These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9484774)

  • 21. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary.
    Reinholz MM; Zschunke MA; Roche PC
    Gynecol Oncol; 2000 Nov; 79(2):264-71. PubMed ID: 11063655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic structure of the candidate proto-oncogene BCL3.
    McKeithan TW; Ohno H; Dickstein J; Hume E
    Genomics; 1994 Nov; 24(1):120-6. PubMed ID: 7896265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization.
    Liu Y
    Gene; 1998 Jul; 215(1):159-69. PubMed ID: 9666114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of alternatively spliced chicken c-myb exon 9A among hematopoietic tissues.
    Schuur ER; Rabinovich JM; Baluda MA
    Oncogene; 1994 Nov; 9(11):3363-5. PubMed ID: 7936662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing.
    Rodrigues GA; Naujokas MA; Park M
    Mol Cell Biol; 1991 Jun; 11(6):2962-70. PubMed ID: 1710022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site.
    Lee CC; Yamada KM
    J Biol Chem; 1994 Jul; 269(30):19457-61. PubMed ID: 7518457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
    Salgia R; Sattler M; Scheele J; Stroh C; Felip E
    Cancer Treat Rev; 2020 Jul; 87():102022. PubMed ID: 32334240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. During in vivo maturation of eukaryotic nuclear mRNA, splicing yields excised exon circles.
    Bailleul B
    Nucleic Acids Res; 1996 Mar; 24(6):1015-9. PubMed ID: 8604331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative splicing of the ret proto-oncogene at intron 4.
    Xing S; Tong Q; Suzuki T; Jhiang SM
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1526-32. PubMed ID: 7811232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure and expression of the human MTG8/ETO gene.
    Wolford JK; Prochazka M
    Gene; 1998 May; 212(1):103-9. PubMed ID: 9661669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exon Definition Facilitates Reliable Control of Alternative Splicing in the RON Proto-Oncogene.
    Enculescu M; Braun S; Thonta Setty S; Busch A; Zarnack K; König J; Legewie S
    Biophys J; 2020 Apr; 118(8):2027-2041. PubMed ID: 32336349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.
    Gray MJ; Kannu P; Sharma S; Neyt C; Zhang D; Paria N; Daniel PB; Whetstone H; Sprenger HG; Hammerschmidt P; Weng A; Dupuis L; Jobling R; Mendoza-Londono R; Dray M; Su P; Wilson MJ; Kapur RP; McCarthy EF; Alman BA; Howard A; Somers GR; Marshall CR; Manners S; Flanagan AM; Rathjen KE; Karol LA; Crawford H; Markie DM; Rios JJ; Wise CA; Robertson SP
    Am J Hum Genet; 2015 Dec; 97(6):837-47. PubMed ID: 26637977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
    Cortot AB; Kherrouche Z; Descarpentries C; Wislez M; Baldacci S; Furlan A; Tulasne D
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
    Drilon A
    Clin Cancer Res; 2016 Jun; 22(12):2832-4. PubMed ID: 27009743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
    Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
    J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
    Fujino T; Suda K; Sakai K; Murakami I; Shimizu S; Ohara S; Koga T; Hamada A; Soh J; Nishio K; Mitsudomi T
    Clin Lung Cancer; 2022 May; 23(3):e185-e195. PubMed ID: 34702670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. cMET Exon 14 Skipping: From the Structure to the Clinic.
    Van Der Steen N; Giovannetti E; Pauwels P; Peters GJ; Hong DS; Cappuzzo F; Hirsch FR; Rolfo C
    J Thorac Oncol; 2016 Sep; 11(9):1423-32. PubMed ID: 27223456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DNA replication licensing factor miniature chromosome maintenance 7 is essential for RNA splicing of epidermal growth factor receptor, c-Met, and platelet-derived growth factor receptor.
    Chen ZH; Yu YP; Michalopoulos G; Nelson J; Luo JH
    J Biol Chem; 2015 Jan; 290(3):1404-11. PubMed ID: 25425645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immortalizing hepatocytes with truncated MET: a little bit of gene goes a long way.
    Sirica AE
    Hepatology; 1997 Aug; 26(2):510-2. PubMed ID: 9252170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.